Company intelligence / Profile preview
Dyna Therapeutics
Waltham, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Dyne Therapeutics has released initial positive clinical data in 2023 and 2024 from its ongoing Phase 1/2 trials (ACHIEVE and DELIVER) that demonstrate successful delivery of oligonucleotide therapeutics to muscle tissue and early impact on disease biomarkers in myotonic dystrophy type 1 and Duchenne muscular dystrophy.
- Therapeutic areas
- NeurologyRare Diseases
- Modalities
- AntibodyAntisense oligonucleotideOligonucleotide
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Dyna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dyna Therapeutics.